Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy

Eugenio Maiorano, Meredith M. Regan, Giuseppe Viale, Mauro G. Mastropasqua, Marco Colleoni, Monica Castiglione-Gertsch, Karen N. Price, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predictive value of CNF in two randomized clinical trials comparing chemoendocrine therapy with endocrine therapy alone in patients with node-negative breast cancer. A total of 1,850 patients randomly assigned to treatment groups comparing endocrine with chemoendocrine therapy, and with centrally-assessed CNF, ER, PgR and HER2 were included in the analytic cohort. The median follow up was 10 years. CNF was present in 84 of 1,850 trial patients (4.5%). It was associated with tumor characteristics suggesting poor outcome, but was an independent adverse factor for disease-free survival. In the presence of CNF outcome was worse regardless of tumor grade, whereas in the absence of CNF, patients with grade 3 tumors had poorer outcome than those with grade 1-2 tumors. Among patients with estrogen receptor-absent tumors chemoendocrine therapy was superior to endocrine therapy alone only in the absence of CNF [HR (chemoendocrine:endocrine) = 0.46 in CNF-absent, 0.90 in CNF-present], while among those with receptor-positive disease chemoendocrine therapy was beneficial only in the presence of CNF [HR = 0.34 CNF-present, 0.96 CNF-absent]. The results suggest that the presence of CNF reflects a biological difference in early breast cancer that is important in modulating the efficacy of standard therapies. Accordingly we believe that its presence should be routinely reported.

Original languageEnglish
Pages (from-to)211-218
Number of pages8
JournalBreast Cancer Research and Treatment
Volume121
Issue number1
DOIs
Publication statusPublished - May 2010

Fingerprint

Fibrosis
Necrosis
Breast Neoplasms
Therapeutics
Neoplasms
Estrogen Receptors
Disease-Free Survival
Randomized Controlled Trials

Keywords

  • Breast cancer
  • Central necrosis
  • Chemotherapy
  • Endocrine therapy
  • Fibrosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer : Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. / Maiorano, Eugenio; Regan, Meredith M.; Viale, Giuseppe; Mastropasqua, Mauro G.; Colleoni, Marco; Castiglione-Gertsch, Monica; Price, Karen N.; Gelber, Richard D.; Goldhirsch, Aron; Coates, Alan S.

In: Breast Cancer Research and Treatment, Vol. 121, No. 1, 05.2010, p. 211-218.

Research output: Contribution to journalArticle

Maiorano, Eugenio ; Regan, Meredith M. ; Viale, Giuseppe ; Mastropasqua, Mauro G. ; Colleoni, Marco ; Castiglione-Gertsch, Monica ; Price, Karen N. ; Gelber, Richard D. ; Goldhirsch, Aron ; Coates, Alan S. / Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer : Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy. In: Breast Cancer Research and Treatment. 2010 ; Vol. 121, No. 1. pp. 211-218.
@article{2cba09707fcd42d8b57dadec84172826,
title = "Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy",
abstract = "A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predictive value of CNF in two randomized clinical trials comparing chemoendocrine therapy with endocrine therapy alone in patients with node-negative breast cancer. A total of 1,850 patients randomly assigned to treatment groups comparing endocrine with chemoendocrine therapy, and with centrally-assessed CNF, ER, PgR and HER2 were included in the analytic cohort. The median follow up was 10 years. CNF was present in 84 of 1,850 trial patients (4.5{\%}). It was associated with tumor characteristics suggesting poor outcome, but was an independent adverse factor for disease-free survival. In the presence of CNF outcome was worse regardless of tumor grade, whereas in the absence of CNF, patients with grade 3 tumors had poorer outcome than those with grade 1-2 tumors. Among patients with estrogen receptor-absent tumors chemoendocrine therapy was superior to endocrine therapy alone only in the absence of CNF [HR (chemoendocrine:endocrine) = 0.46 in CNF-absent, 0.90 in CNF-present], while among those with receptor-positive disease chemoendocrine therapy was beneficial only in the presence of CNF [HR = 0.34 CNF-present, 0.96 CNF-absent]. The results suggest that the presence of CNF reflects a biological difference in early breast cancer that is important in modulating the efficacy of standard therapies. Accordingly we believe that its presence should be routinely reported.",
keywords = "Breast cancer, Central necrosis, Chemotherapy, Endocrine therapy, Fibrosis",
author = "Eugenio Maiorano and Regan, {Meredith M.} and Giuseppe Viale and Mastropasqua, {Mauro G.} and Marco Colleoni and Monica Castiglione-Gertsch and Price, {Karen N.} and Gelber, {Richard D.} and Aron Goldhirsch and Coates, {Alan S.}",
year = "2010",
month = "5",
doi = "10.1007/s10549-009-0360-y",
language = "English",
volume = "121",
pages = "211--218",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer

T2 - Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy

AU - Maiorano, Eugenio

AU - Regan, Meredith M.

AU - Viale, Giuseppe

AU - Mastropasqua, Mauro G.

AU - Colleoni, Marco

AU - Castiglione-Gertsch, Monica

AU - Price, Karen N.

AU - Gelber, Richard D.

AU - Goldhirsch, Aron

AU - Coates, Alan S.

PY - 2010/5

Y1 - 2010/5

N2 - A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predictive value of CNF in two randomized clinical trials comparing chemoendocrine therapy with endocrine therapy alone in patients with node-negative breast cancer. A total of 1,850 patients randomly assigned to treatment groups comparing endocrine with chemoendocrine therapy, and with centrally-assessed CNF, ER, PgR and HER2 were included in the analytic cohort. The median follow up was 10 years. CNF was present in 84 of 1,850 trial patients (4.5%). It was associated with tumor characteristics suggesting poor outcome, but was an independent adverse factor for disease-free survival. In the presence of CNF outcome was worse regardless of tumor grade, whereas in the absence of CNF, patients with grade 3 tumors had poorer outcome than those with grade 1-2 tumors. Among patients with estrogen receptor-absent tumors chemoendocrine therapy was superior to endocrine therapy alone only in the absence of CNF [HR (chemoendocrine:endocrine) = 0.46 in CNF-absent, 0.90 in CNF-present], while among those with receptor-positive disease chemoendocrine therapy was beneficial only in the presence of CNF [HR = 0.34 CNF-present, 0.96 CNF-absent]. The results suggest that the presence of CNF reflects a biological difference in early breast cancer that is important in modulating the efficacy of standard therapies. Accordingly we believe that its presence should be routinely reported.

AB - A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predictive value of CNF in two randomized clinical trials comparing chemoendocrine therapy with endocrine therapy alone in patients with node-negative breast cancer. A total of 1,850 patients randomly assigned to treatment groups comparing endocrine with chemoendocrine therapy, and with centrally-assessed CNF, ER, PgR and HER2 were included in the analytic cohort. The median follow up was 10 years. CNF was present in 84 of 1,850 trial patients (4.5%). It was associated with tumor characteristics suggesting poor outcome, but was an independent adverse factor for disease-free survival. In the presence of CNF outcome was worse regardless of tumor grade, whereas in the absence of CNF, patients with grade 3 tumors had poorer outcome than those with grade 1-2 tumors. Among patients with estrogen receptor-absent tumors chemoendocrine therapy was superior to endocrine therapy alone only in the absence of CNF [HR (chemoendocrine:endocrine) = 0.46 in CNF-absent, 0.90 in CNF-present], while among those with receptor-positive disease chemoendocrine therapy was beneficial only in the presence of CNF [HR = 0.34 CNF-present, 0.96 CNF-absent]. The results suggest that the presence of CNF reflects a biological difference in early breast cancer that is important in modulating the efficacy of standard therapies. Accordingly we believe that its presence should be routinely reported.

KW - Breast cancer

KW - Central necrosis

KW - Chemotherapy

KW - Endocrine therapy

KW - Fibrosis

UR - http://www.scopus.com/inward/record.url?scp=77951298251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951298251&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0360-y

DO - 10.1007/s10549-009-0360-y

M3 - Article

C2 - 19280340

AN - SCOPUS:77951298251

VL - 121

SP - 211

EP - 218

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -